NCT05645627View on ClinicalTrials.gov

A Study to Evaluate IBI112 in the Treatment of Psoriasis With Moderate to Severe Plaque Psoriasis

PHASE3CompletedINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

February 10, 2023

Primary Completion Date

August 9, 2023

Study Completion Date

August 1, 2024

Conditions
Psoriasis
Interventions
DRUG

IBI112

IBI112 by subcutaneous injection through week 16 ,and then will receive Dose 3 IBI112 by subcutaneous injection through week 48

DRUG

placebo /IBI112

placebo by subcutaneous injection cross over IBI112 by subcutaneous injection at week 16 through week 48

DRUG

IBI112

IBI112 by subcutaneous injection through week 16 ,and then will receive Dose 3 IBI112 by subcutaneous injection through week 48

Trial Locations (1)

200443

Shanghai Skin Disease Hospital, Shanghai

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY